GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Cyclically Adjusted PB Ratio

ORMP (Oramed Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.75 (As of May. 27, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-27), Oramed Pharmaceuticals's current share price is $2.14. Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $2.85. Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.75.

The historical rank and industry rank for Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

ORMP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.7   Med: 3.18   Max: 16.95
Current: 0.76

During the past years, Oramed Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 16.95. The lowest was 0.70. And the median was 3.18.

ORMP's Cyclically Adjusted PB Ratio is ranked better than
63.68% of 669 companies
in the Biotechnology industry
Industry Median: 1.48 vs ORMP: 0.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $3.447. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.85 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Oramed Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.39 11.67 5.32 0.88 0.86

Oramed Pharmaceuticals Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 0.94 0.88 0.86 0.75

Competitive Comparison of Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.14/2.85
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Oramed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.447/134.9266*134.9266
=3.447

Current CPI (Mar. 2025) = 134.9266.

Oramed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201505 1.968 100.333 2.647
201508 2.147 100.548 2.881
201511 1.943 100.135 2.618
201602 2.495 100.040 3.365
201605 2.360 101.355 3.142
201608 1.987 101.617 2.638
201611 1.808 101.829 2.396
201702 1.604 102.779 2.106
201705 1.487 103.256 1.943
201708 1.407 103.587 1.833
201711 1.589 104.072 2.060
201802 1.422 105.052 1.826
201805 1.151 106.148 1.463
201808 1.791 106.383 2.272
201811 1.661 106.338 2.108
201902 1.458 106.649 1.845
201905 1.240 108.048 1.548
201908 1.116 108.245 1.391
201911 0.986 108.519 1.226
202002 0.697 109.139 0.862
202005 1.465 108.175 1.827
202008 1.389 109.662 1.709
202011 1.185 109.793 1.456
202102 1.748 110.968 2.125
202105 2.232 113.576 2.652
202108 3.280 115.421 3.834
202111 4.468 117.269 5.141
202203 4.210 121.301 4.683
202206 3.986 125.017 4.302
202209 3.932 125.227 4.237
202212 3.837 125.222 4.134
202303 3.777 127.348 4.002
202306 3.768 128.729 3.949
202309 3.702 129.860 3.846
202312 4.061 129.419 4.234
202403 4.113 131.776 4.211
202406 4.358 132.554 4.436
202409 3.891 133.029 3.947
202412 3.664 133.157 3.713
202503 3.447 134.927 3.447

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals  (NAS:ORMP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Oramed Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Executives
Benjamin Shapiro director 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron director, 10 percent owner 142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov director 9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron director 2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz officer: Chief Commercial Officer 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer director MORAN 16, KFAR SABA L3 4428890
Netanel Derovan officer: Chief Legal Officer 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman officer: Chief Financial Officer 20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin director 36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz officer: Chief Commercial Officer MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank director 3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming director 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay officer: CFO, Treasurer and Secretary 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton officer: VP Business Development 13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman director HADASSA 6, TEL AVIV L3 6451306